2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Adverse Events, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

3387 Vicrimenib (BN104) combined with chemotherapy or venetoclax/azacitadine in patients with acute myeloid leukemia: Preliminary results of an open-label, phase I/II study

Haiping Dai, Zhenfang Liu, MD2, Yue Pan3, Depei Wu Sr, MD4, Suning Chen, MD, PhD5
1 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou, China
2 The First Affiliated Hospital of Guangxi Medical University, Nanning, China
3 Medical Affairs Department, Beijing, China
4 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou, China
5 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou, China

Background: Vicrimenib (BN104/S243249), a small-molecule menin inhibitor, demonstrated robust antileukemic efficacy and favorable tolerability in patients with relapsed/refractory (R/R) acute leukemia in a phase 1/2 study (NCT06052813), achieving an overall response rate of 88.9%. However, the safety and efficacy of vicrimenib combined therapy in acute myeloid leukemia (AML) have not yet been characterized.

Methods: This is an open-label, multicenter, phase 1/2 study (NCT06746519) conducted in patients aged ≥18 years with AML, either confirmed KMT2A/NUP98 rearrangement (KMT2Ar/NUP98r), KMT2A-PTD or NPM1 mutation (NPM1m) with intermediate or adverse risk. The trial consists of 3 cohorts: Cohort A enrolled untreated AML patients eligible for intensive chemotherapy. Cohort B enrolled untreated AML patients ineligible for intensive chemotherapy. Cohort C enrolled patients with R/R AML, including those with documented resistance to vicrimenib monotherapy. Patients in cohort A received induction with vicrimenib plus idarubicin 12mg/m2 on days 1-3 and cytarabine 100mg/m2 on days 1-7, followed by up to 4 cycles of high-dose cytarabine plus vicrimenib consolidation. Patients in cohorts B and C received induction with vicrimenib, venetoclax (cycle 1 given as dose escalation from 100 mg on day 1, 200 mg on day 2 and 400mg on day 3 and beyond) and azacitidine (75mg/m2 on days 1-7) (VA). Allogenic stem cell transplantation (allo-HSCT) can be implemented following achievement of complete remission (CR). Across all cohorts, vicrimenib was administrated using a 3+3 dose-escalation design (200mg BID, 400mg BID or 600mg BID), starting on day 4 of cycle 1 and day 1 of subsequent cycles. The primary endpoints were safety and recommended phase 2 dose. Secondary endpoints included composite CR (CRc, defined as CR+CRh+CRi) rate, CR rate, duration of remission and overall survival (OS). Study enrollment was prematurely discontinued as of Sep 1, 2025, following sponsor decision.

Results:

From Nov 2024, 27 patients were screened for eligibility, with 26 ultimately enrolled. The median age of the patients was 40.5(range: 30-58) years, and 12 (46.2%) were male. Among them , 24 (92.3%) had de novo AML, while 2 (7.7%) had secondary AML. Twenty patients (76.9%) were newly diagnosed AML, 2 (7.7%) were relapsed AML and 4 (15.4%) were refractory AML. Four patients (15.4%) had prior exposure to vicrimenib. Risk stratification per ELN criteria revealed intermediate risk in 7 (26.9%) and adverse risk in 19 (73.1%) patients . Seventeen patients had KMT2Ar , 4 had KMT2A-PTD, 4 had NUP98r and 1 had NPM1m. All 26 enrolled patients were evaluable for efficacy and safety. Overall, 22 patients (84.6%) achieved CRc, all were CR. Four patients showed no response. The CRc rates in untreated AML and R/R AML were 90% (18/20) and 66.7% (4/6), respectively, and all were CR. Among treatment-naïve patients, the CR rates were 87.5% (7/8) and 91.7% (11/12) in those receiving vicrimenib plus intensive chemotherapy and plus VA, respectively. The CR rate was 66.7% (4/6) for R/R AML who received vicrimenib plus VA. The 12-month duration of remission rate was 84.7% (95% CI, 59.7-94.8). At the data cutoff date (Jun 1, 2026), only 1 patient had died (due to cerebral hemorrhage unrelated to vicrimenib), and the 12-month OS rate was 91.4% (95% CI, 69.8-97.8). Of the 17 KMT2Ar patients, 15 (88.2%) achieved CR, with 13 (76.5%; 95% CI, 50.1-93.2) attained MRD negative CR. Among the 4 KMT2A-PTD patients, 2 achieved CR, with 1 achieved MRD negative CR. Among 5 patients with other rearrangements, all achieved CR, and 4 (80%) attained MRD negative CR.

Grade ≥3 infections occurred in 12 patients (46.2%), with rates of 62.5% (5/8) in patients receiving vicrimenib plus chemotherapy and 38.9% (7/18) in those receiving vicrimenib plus VA. Sepsis was reported in 1 patient treated with vicrimenib plus chemotherapy, with no cases observed in those receiving vicrimenib plus VA. One patient in the VA group experienced differentiation syndrome. Grade ≥3 QTc prolongation was observed in 2 patients: 1 received vicrimenib plus chemotherapy and 1 was received vicrimenib plus VA.

Conclusion: Vicrimenib-based combination therapies demonstrate high response rates in treatment-naïve AML and notable efficacy in R/R AML with vicrimenib resistance. When combined with VA, vicrimenib exhibits comparable efficacy to intensive chemotherapy combinations, with a favorable safety profile.

Haiping Dai: No relevant conflicts of interest to declare.